Table 1. AML patient characteristics included in this study (n=18).
| # | Age | Risk factor | Risk | IC50 control | IC50 SN | resistance factor | Induction chemotherapy | Induction remision | Consolidation chemotherapy | Allogeneic SCT | Relapse | Survival (days) | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 38 | NPM1 mut | low | 3,8 ± 0,8 | 2,4 ± 1,5 | 0.6 | 7+3 | CR | HiDAC x 2 | no | no | 548 | alive |
| 2 | 29 | t(16;16) | low | 2,8 ± 0,8 | 1,0 ± 0,2 | 0.4 | 7+3 | CR | HiDAC x 2 | no | no | 484 | alive |
| 3 | 57 | t(8;21) | low | 3,8 ± 0,8 | 3,2 ± 1,3 | 0.8 | 7+3 | CR | HiDAC x 2 | no | no | 547 | alive |
| 4 | 56 | intermediate | 4,7 ± 0,4 | 1,8 ± 0,2 | 0.4 | 7+3 | CR | HiDAC x 2 | no | yes | 564 | death | |
| 5 | 55 | intermediate | 4,3 ± 0,7 | 2,8 ± 1,1 | 0.7 | 7+3 | CR | HAM | no | no | 1137 | alive | |
| 6 | 42 | intermediate | 4,3 ± 0,8 | 16,6 ± 0,8 | 3.9 | 7+3 | CR | HAM x 2 | no | yes | 336 | death | |
| 7 | 62 | > 60 years | high | 4,7 ± 0,4 | 1,9 ± 0,1 | 0.4 | 7+3 | CR | HiDAC x 2 | no | no | 1124 | alive |
| 8 | 45 | complex cariotipe | high | 2,6 ± 0,6 | 1,2 ± 0,1 | 0.5 | 7+3 | CR | Azacitidina x 6 | no | yes | 227 | death |
| 9 | 37 | > 30,000 blast | high | 4,1 ± 1,2 | 3,0 ± 1,5 | 0.7 | 7+3 | CR | FLAG-IDA, HiDAC x 2 | no | no | 781 | alive |
| 10 | 26 | complex cariotipe | high | 3,1 ± 0,1 | 2,6 ± 0,1 | 0.8 | 7+3 | <5% blast | FLAG-IDA, MEC | yes | no | 735 | alive |
| 11 | 69 | > 60 years | high | 3,1 ± 0,1 | 2,8 ± 0,3 | 0.9 | 7+3 | CR | Azacitidina x 4 | no | yes | 960 | alive |
| 12 | 61 | > 60 years | high | 3,4 ± 0,1 | 3,7 ± 0,1 | 1.1 | No | no | no | no | yes | 292 | death |
| 13 | 74 | > 60 years | high | 4,3 ± 0,7 | 16 ± 0,4 | 3.7 | No | no | no | no | yes | 287 | death |
| 14 | 48 | > 30,000 blast | high | 4,3 ± 0,7 | 16 ± 0,4 | 3.7 | 7+3 | CR | HiDAC x 3 | no | yes | 244 | death |
| 15 | 62 | > 60 years | high | 4,5 ± 0,6 | 45 ± 1,2 | 10.2 | 7+3 | CR | Azacitidina x 6 | no | yes | 357 | death |
| 16 | 33 | AML 2nd relapse | high | 4,0 ± 0,4 | 94 ± 0,4 | 23.5 | FLAG-IDA | CR | HiDAC x 1 | yes | yes | 523 | death |
| 17 | 37 | complex cariotipe | high | 3,4 ± 0,1 | 102 ± 0,4 | 30.0 | 7+3 | <5% blast | HiDAC x 1 | no | yes | 52 | death |
| 18 | 85 | > 60 years | high | 2,1 ± 0,1 | 67,3 ± 0,4 | 32.0 | No | no | no | no | yes | 45 | death |
Abbreviations: IC50 control, IC50 using normal growth medium; IC50 SN, IC50 using supernatant from BMSCs; NPMI1, Nucleophosmin; RF2, Resistance factor; Chemo3, chemotherapy; 7+34, Ara-C (7 days) and Daunorrubicin (3 days); CR5, complete remission; HiDAC6, High-dose Ara-C; t(16;16)7, translocation (16;16); Int8, intermediate; HAM9, High-dose Ara-C and Mitoxantrone. FLAG-IDA10, Fludarabine, Ara-C, Idarrubicin and G-CSF; MEC11, Mitoxantrone, Etoposide and cytarabine (Ara-C).